Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage III, IV, or recurrent mantle cell lymphoma~  * CD5 positive OR~ * Evidence of bcl-1 oncogene overexpression~* Measurable or evaluable disease with at least one of the following:~  * Clear cut radiographic findings~ * Clearly defined bidimensional defect or mass at least 2 cm in diameter on radionuclide or CT scan~ * Enlarged spleen extending at least 2 cm below costal margin with lymphomatous involvement only~ * Enlarged liver with proof of lymphoma by biopsy~* CNS involvement allowed~* Fully HLA matched donor for allogeneic transplantation~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-3~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Bilirubin no greater than 3.0 mg/dL~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No significant cardiac disease~Other:~* No other prior malignancies except previously treated nonmelanoma skin cancer or carcinoma in situ of the cervix~* No other medical problems that would preclude study~* HIV negative~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~Chemotherapy:~* See Disease Characteristics~* Prior chemotherapy, including doxorubicin, allowed~Endocrine therapy:~* See Disease Characteristics~* Prior steroids allowed~Radiotherapy:~* See Disease Characteristics~* Prior radiotherapy allowed excluding the indicator lesions~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).